Pfizer PFE
SEC filings (XBRL) · quarterly · fiscal year ends December 31
Pick a second metric to compare.
Source: SEC EDGAR 10-Q/10-K XBRL, CIK 78003; every value is traced to its filing on EDGAR. Retrieved Oct 11, 2026. Quarters labelled by fiscal quarter with the calendar period end. Q4 = annual minus Q1–Q3; cash-flow quarters derived from year-to-date figures.
Last 84 quarters
| Q3 2024Sep 29, 2024 | Q4 2024Dec 31, 2024 | Q1 2025Mar 30, 2025 | Q2 2025Jun 29, 2025 | Q3 2025Sep 28, 2025 | Q4 2025Dec 31, 2025 | Q1 2026Mar 29, 2026 | Q2 2026Jun 28, 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $17.7B | $17.8B | $13.7B | $14.7B | $16.7B | $17.6B | $14.5B | $15.0B |
| Operating income | — No figure for Q2 2009–Q2 2026: No us-gaap:OperatingIncomeLoss fact in any Pfizer filing; the income statement goes from costs to income before taxes with no operating-income subtotal. | — No figure for Q2 2009–Q2 2026: No us-gaap:OperatingIncomeLoss fact in any Pfizer filing; the income statement goes from costs to income before taxes with no operating-income subtotal. | — No figure for Q2 2009–Q2 2026: No us-gaap:OperatingIncomeLoss fact in any Pfizer filing; the income statement goes from costs to income before taxes with no operating-income subtotal. | — No figure for Q2 2009–Q2 2026: No us-gaap:OperatingIncomeLoss fact in any Pfizer filing; the income statement goes from costs to income before taxes with no operating-income subtotal. | — No figure for Q2 2009–Q2 2026: No us-gaap:OperatingIncomeLoss fact in any Pfizer filing; the income statement goes from costs to income before taxes with no operating-income subtotal. | — No figure for Q2 2009–Q2 2026: No us-gaap:OperatingIncomeLoss fact in any Pfizer filing; the income statement goes from costs to income before taxes with no operating-income subtotal. | — No figure for Q2 2009–Q2 2026: No us-gaap:OperatingIncomeLoss fact in any Pfizer filing; the income statement goes from costs to income before taxes with no operating-income subtotal. | — No figure for Q2 2009–Q2 2026: No us-gaap:OperatingIncomeLoss fact in any Pfizer filing; the income statement goes from costs to income before taxes with no operating-income subtotal. |
| Net income | $4.5B | $0.4B | $3.0B | $2.9B | $3.5B | −$1.6B | $2.7B | −$0.2B |
| Capital spending | $0.7B | $0.9B | $0.6B | $0.6B | $0.6B | $0.8B | $0.4B | $0.5B |
| Operating cash flow | $6.7B | $6.7B | $2.3B | −$0.6B | $4.6B | $5.3B | $2.6B | $0.8B |
| Free cash flow | $6.1B | $5.8B | $1.8B | −$1.2B | $4.0B | $4.5B | $2.2B | $0.3B |
| Capex / operating cash flow | 9.7% | 13.6% | 24.1% | — No figure for Q2 2025: Both inputs reported, but OCF is not positive, so capex/OCF is not meaningful and is left blank (not a data gap; the reason set has no closer value). | 13.1% | 15.8% | 16.7% | 63.8% |
| Shares outstanding | 5.667B | 5.667B | 5.685B | 5.686B | 5.686B | 5.686B | 5.699B | 5.700B |
| Share count change, y/y | +0.4% | +0.4% | +0.3% | +0.3% | +0.3% | +0.3% | +0.2% | +0.2% |
| Diluted shares (weighted avg.) | 5.705B | — No figure for Q4 2024: Fiscal Q4: the 10-K gives only the 12-month weighted average; a quarterly weighted average cannot be derived by subtraction. | 5.710B | 5.706B | 5.714B | — No figure for Q4 2025: Fiscal Q4: the 10-K gives only the 12-month weighted average; a quarterly weighted average cannot be derived by subtraction. | 5.731B | 5.699B |
Operating income: Not presented by the company: No us-gaap:OperatingIncomeLoss fact in any Pfizer filing; the income statement goes from costs to income before taxes with no operating-income subtotal..
— Capex / operating cash flow: No figure for Q2 2025: Both inputs reported, but OCF is not positive, so capex/OCF is not meaningful and is left blank (not a data gap; the reason set has no closer value).
— Diluted shares (weighted avg.): No figure for Q4 2024: Fiscal Q4: the 10-K gives only the 12-month weighted average; a quarterly weighted average cannot be derived by subtraction.
— Diluted shares (weighted avg.): No figure for Q4 2025: Fiscal Q4: the 10-K gives only the 12-month weighted average; a quarterly weighted average cannot be derived by subtraction.
Diluted shares (weighted avg.): fiscal Q4 is blank because the 10-K gives 12-month figures only.
XBRL tags used
| Revenue | SalesRevenueNet | Jun 2009 to Jun 2014 |
|---|---|---|
SalesRevenueGoodsNet | Sep 2014 to Apr 2017 | |
RevenueFromContractWithCustomerExcludingAssessedTax | Jul 2017 to Dec 2021 | |
Revenues | Apr 2022 to Jun 2026 | |
| Operating income | Not presented by the company: No us-gaap:OperatingIncomeLoss fact in any Pfizer filing; the income statement goes from costs to income before taxes with no operating-income subtotal. | |
| Net income | NetIncomeLoss | Jun 2009 to Jun 2026 |
| Capital spending | PaymentsToAcquirePropertyPlantAndEquipment | Jun 2009 to Jun 2026 |
| Operating cash flow | NetCashProvidedByUsedInOperatingActivities | Jun 2009 to Jun 2026 |
| Free cash flow | ocf - capex: NetCashProvidedByUsedInOperatingActivities, PaymentsToAcquirePropertyPlantAndEquipment | Jun 2009 to Jun 2026 |
| Capex / operating cash flow | capex / ocf * 100: PaymentsToAcquirePropertyPlantAndEquipment, NetCashProvidedByUsedInOperatingActivities | Jun 2009 to Jun 2026 |
| Shares outstanding | dei:EntityCommonStockSharesOutstanding | Jun 2009 to Jun 2026 |
| Diluted shares (weighted avg.) | WeightedAverageNumberOfDilutedSharesOutstanding | Jun 2009 to Jun 2026 |
Where a company changed tags, each quarter uses the tag it was reported under; the newest tag is primary.